News
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...
A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...
Two Indian nationals were sentenced to 30 months in prison for smuggling counterfeit cancer drugs into the US.
Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...
Two brothers from India were sentenced to 30 months in prison after they were found guilty of trying to sell counterfeit, ...
In 2023, Varda sent a pharma manufacturing capsule into space to test a crystallisation process for HIV therapy ritonavir, a ...
This is an audio transcript of the FT News Briefing podcast episode: ‘Big Pharma markets left in a ‘patent cliff’-hanger’ ...
Two Indian brothers received 30 months in prison for selling counterfeit drugs to U.S. patients, endangering lives across the country.
The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results